Headlines

New lab software connector by LabWare and Mettler Toledo launched

LabWare Inc. and Mettler Toledo have announced a game-changing collaboration aimed at transforming laboratory productivity through a new, plug-and-play software integration.

Seqster and PatientsLikeMe partner to enhance patient data engagement

Seqster and PatientsLikeMe have announced a strategic partnership to integrate real-time electronic health record (EHR) data with patient engagement tools, aiming to significantly improve clinical research and patient outcomes.

AI-driven insights: SOMS boosts clinical trial success

In an in-depth conversation, OSP senior editor, Liza Laws, interviews Adrian Kizewski, associate director at IQVIA, to uncover the transformative impact of the Sub-population Optimization & Modeling Solution (SOMS) on clinical trials.

Reimagine Care and Memorial Hermann boost cancer care engagement

Reimagine Care, the leading provider of on-demand cancer care, and Memorial Hermann Health System, one of Texas's largest not-for-profit health systems, have announced an ambitious multi-year expansion of their pioneering partnership.

New collaboration aims to streamline clinical trial access for patients

Global health technology company myTomorrows announced a new partnership on Tuesday (Aug 27) with Pancreatic Cancer Europe (PCE), a multi-stakeholder platform dedicated to improving care for pancreatic cancer patients.

Metagenomics revolution: Empress Therapeutics on drug discovery breakthroughs

Dr Dawn Thompson has over 20 years of experience in building technology platforms that leverage genomics at scale to produce novel products.

ARS Pharmaceuticals’ EURneffy: A new era in needle-free emergency allergy treatment

The European Commission has approved ARS Pharmaceuticals’ adrenaline nasal spray for the emergency treatment of severe allergies, EURneffy.

UCB advances innovation strategy with $680M divestment deal in China

UCB, a global biopharmaceutical leader, has taken a significant step in refining its strategic focus by divesting its mature neurology and allergy portfolio in China.

‘We’re here and we’re ready’ - Dalgety secures UK licence to supply medical cannabis

Dalgety, one of the UK's leading medical cannabis cultivators, has achieved a significant milestone by securing a Home Office licence to supply medical cannabis within the UK.

Astellas begins phase 3 trial of fezolinetant for VMS in breast cancer

Astellas Pharma Inc. has announced the initiation of its phase 3 pivotal study, Highlight 1, for fezolinetant, an investigational nonhormonal oral treatment for vasomotor symptoms (VMS) in women with breast cancer receiving adjuvant endocrine therapy.

ALZpath and Beckman Coulter partner for breakthrough diagnostic

In the ongoing battle against Alzheimer’s disease, early diagnosis is crucial.

Nasal powder shows promise in boosting immune defense

The INNA-051 formulation is designed to enhance the body’s natural immune response, targeting individuals aged 60 and over who are at increased risk for complications from respiratory viral infections.

First severe plaque psoriasis oral therapy for ages 6-17 available in the US

Amgen has announced the US availability of Otezla (apremilast) for pediatric patients aged 6 to 17 with moderate to severe plaque psoriasis.

Melanie Adams-Cioaba on leading the cryo-EM revolution in drug discovery

Breaking barriers in science: Thermo Fisher's Melanie Adams-Cioaba on innovation and inclusion

In the rapidly evolving field of drug discovery, Melanie Adams-Cioaba stands at the forefront, leading transformative advancements in cryo-electron microscopy (cryo-EM) at Thermo Fisher Scientific.

Gilead's Livdelzi granted accelerated FDA approval for primary biliary cholangitis

Gilead Sciences, Inc. has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare and chronic autoimmune disease affecting the bile...

Ayvakit's explosive 185% revenue growth: A game-changer in rare disease treatment

Ayvakit, a groundbreaking therapy developed by Blueprint Medicines, has witnessed a remarkable 185% year-over-year revenue growth in the second quarter of this year (2024).

Bavarian Nordic readies 2 million vaccine doses to fight mpox outbreak

The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organization’s declaration of mpox as a Public Health Emergency of International Concern (PHEIC) earlier this month.